RT Journal Article
SR Electronic
T1 Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.18.20038018
DO 10.1101/2020.03.18.20038018
A1 Quan-xin Long
A1 Hai-jun Deng
A1 Juan Chen
A1 Jie-li Hu
A1 Bei-zhong Liu
A1 Pu Liao
A1 Yong Lin
A1 Li-hua Yu
A1 Zhan Mo
A1 Yin-yin Xu
A1 Fang Gong
A1 Gui-cheng Wu
A1 Xian-xiang Zhang
A1 Yao-kai Chen
A1 Zhi-jie Li
A1 Kun Wang
A1 Xiao-li Zhang
A1 Wen-guang Tian
A1 Chang-chun Niu
A1 Qing-jun Yang
A1 Jiang-lin Xiang
A1 Hong-xin Du
A1 Hua-wen Liu
A1 Chun-hui Lang
A1 Xiao-He Luo
A1 Shao-bo Wu
A1 Xiao-ping Cui
A1 Zheng Zhou
A1 Jing Wang
A1 Cheng-jun Xue
A1 Xiao-feng Li
A1 Li Wang
A1 Xiao-jun Tang
A1 Yong Zhang
A1 Jing-fu Qiu
A1 Xia-mao Liu
A1 Jin-jing Li
A1 De-chun Zhang
A1 Fan Zhang
A1 Xue-fei Cai
A1 De-qiang Wang
A1 Yuan Hu
A1 Ji-hua Ren
A1 Ni Tang
A1 Ping Liu
A1 Qin Li
A1 Ai-long Huang
YR 2020
UL http://medrxiv.org/content/early/2020/03/20/2020.03.18.20038018.abstract
AB Background We aim to investigate the profile of acute antibody response in COVID-19 patients, and provide proposals for the usage of antibody test in clinical practice.Methods A multi-center cross-section study (285 patients) and a single-center follow-up study (63 patients) were performed to investigate the feature of acute antibody response to SARS-CoV-2. A cohort of 52 COVID-19 suspects and 64 close contacts were enrolled to evaluate the potentiality of the antibody test.Results The positive rate for IgG reached 100% around 20 days after symptoms onset. The median day of seroconversion for both lgG and IgM was 13 days after symptoms onset. Seroconversion of IgM occurred at the same time, or earlier, or later than that of IgG. IgG levels in 100% patients (19/19) entered a platform within 6 days after seroconversion. The criteria of ‘IgG seroconversion’ and ‘> 4-fold increase in the IgG titers in sequential samples’ together diagnosed 82.9% (34/41) of the patients. Antibody test aided to confirm 4 patients with COVID-19 from 52 suspects who failed to be confirmed by RT-PCR and 7 patients from 148 close contacts with negative RT-PCR.Conclusion IgM and IgG should be detected simultaneously at the early phase of infection. The serological diagnosis criterion of seroconversion or the ‘>; 4-fold increase in the IgG titer’ is suitable for a majority of COVID-19 patients. Serologic test is helpful for the diagnosis of SARS-CoV-2 infection in suspects and close contacts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Emergency Project from the Science & Technology Commission of Chongqing; The Major National S&T program grant (2017ZX10202203 and 2017ZX10302201) from Science & Technology Commission of China; The grant (81871635, 81671997 and 81902060) from the National Natural Science Foundation of China, and the grant (20180141 and 20170413) from the Science & Technology Commission of Yuzhong district, Chongqing.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred to in the manuscript are available.